Can a common heart drug reverse scarring in stiff heart failure?
NCT ID NCT06536309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug sacubitril/valsartan can reduce scarring in the heart muscle of people with a type of heart failure called HFpEF (stiff heart). The trial will enroll 36 adults aged 50 and older with heart failure and a normal pumping function. Participants will receive either the study drug or a comparison drug (valsartan alone) for one year, and heart scarring will be measured using MRI scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can shedding pounds reboot the Heart's exercise engine?
- Hormone therapy may shield menopausal hearts and brains — a trial puts it to the test
- Keto vs. Low-Fat: which diet helps heart failure patients move better?
- Zapping lung nerves could ease heart Failure-Related high blood pressure
- Stiff arteries may hold key to heart failure progression
- Simple breathing training may ease heart failure symptoms in seniors